Traders should monitor upcoming IND filing in mid-2026 and any early clinical trial announcements. While preclinical results are encouraging, the stock reaction may reflect heightened expectations—position accordingly ahead of potential clinical milestones or setbacks.
Price Chart
Executive Summary
Prelude Therapeutics announced positive preclinical data for its lead candidate PRT13722, a first-in-class, selective KAT6A degrader for HR+/HER2- breast cancer, showing complete tumor regressions and an improved safety profile. The company remains on track to file an IND in mid-2026 and initiate a Phase 1 trial in the second half of 2026. While the data are promising, they are preclinical and not yet validated in humans.
Key Facts
- PRT13722 is a first-in-class, orally bioavailable, highly selective KAT6A degrader.
- Preclinical data show complete tumor regressions in HR+/HER2- breast cancer models, both in treatment-naive and therapy-experienced settings.
- PRT13722 demonstrates synergy with standard therapies (ET, CDK4/6i, PI3Kαi) and improved hematological safety vs. prifetrastat.
- IND filing expected mid-2026; Phase 1 trial initiation planned for 2H 2026.
- Data presented at AACR Annual Meeting 2026.
Financial Impact
No direct financial impact disclosed; potential long-term value creation if clinical development succeeds.
Risk Factors
- Preclinical results may not translate to clinical efficacy or safety in humans.
- Development timeline delays are possible despite current guidance.
- High valuation risk given small market cap ($280M) and early-stage pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers